Aperture Health, Inc. Enters Into Discussions to Form a Joint Venture to Offer Its’ Services to the Pet Med Marketplace
FAIRFIELD, N.J., Feb. 1, 2012 /PRNewswire/ — Aperture Health, Inc. (OTC: APRE) announced that it has entered into planning discussions with small and large animal veterinarians and other industry professionals, with a specific focus on the equine show and racing disciplines. The Pet Med industry in the United States is in excess of $4B. Aperture’s CEO, James Hennig, R.Ph. became certified in veterinary compounding to be able to move the company into the fast growing pet med arena. Triad has historically been a provider of infusion therapies to major vet hospitals in the metro NJ area.
James Hennig, R.Ph, Chief Executive Officer and Chairman of the Board of Directors commented, “We are very excited at the prospects of forming partnerships and alliances with noted large and small animal Veterinarians and in particular other equine sport professionals who require our capabilities to provide complex compounding and IV services. The rapid growth in this industry and the high margins attributable to penetrating this relatively untapped market will provide Aperture and Triad tremendous opportunity to increase and accelerate revenue and bottom line growth.”
About Aperture Health, and Triad Therapeutics
Aperture Health through its wholly owned subsidiary Triad Therapeutics operates a fully JCAHO accredited home IV therapy company, achieving this “gold standard” status in 2007. The company has built a well respected reputation in its industry for its therapy expertise and commitment to care for its patient clients. The company services clients throughout the States of New Jersey, New York and Connecticut, providing opportunity for organic growth. Triad’s full time marketing and sales personnel continuously represent the company in the core services areas, growing and maintaining the company’s referral source base. Patient referrals are made from physicians, hospitals, insurance companies, veterinarians and hospice care providers that have established a professional rapport with Triad.
Certain statements in this news release are forward-looking, including (without limitation) growing revenues and earnings, expected results from current projects and attracting new business. Undue reliance should not be placed on such forward-looking statements because the matters they describe are subject to known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond the Company’s control. The Company’s actual results, performance and trends could differ materially from those indicated or implied by such statements as a result of various factors, including (without limitation) the continued strengthening of Triad’s selling and marketing functions, continued customer satisfaction, contract renewal, new product development, continued availability of capable dedicated personnel, continued cost management, success and availability of acquisitions, availability of financing and other factors, as well as by factors applicable to most companies such as general economic, competitive and other business and civil conditions. Information regarding certain of those and other risk factors and cautionary statements that could affect future results, performance or trends is discussed in the Company’s OTC Disclosure Statement and unaudited management financials posted on www.pinksheets.com . All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.
SOURCE Aperture Health, Inc.